Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents
Authors:
Open Access
- 1 July 1999
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 13 (7) , 1062-1070
Abstract
The aberrant expression of tissue factor (TF) in acute promyelocytic leukemia (APL) cells has been implicated in the pathogenesis of the APL coagulopathy. In this study, we found that in APL patients receiving ATRA or As2&O3 treatment, the improvement in hypercoagulobility and hyperfibrinolysis paralleled the correction of plasma fibrinogen level and amelioration of bleeding symptoms. Notably, clinical improvement was also correlated to ATRA/As2O3-induced rapid decrease of membrane procoagulant activity (PCA) and TF contents of APL blasts. Consistent with the in vivo findings, the membrane PCA, TF antigen and its mRNA level within NB4 cells were rapidly down-regulated by 1 μM ATRA or As2O3, while 0.2 μg/ml DNR increased these TF parameters prior to its effect upon apoptosis induction. The down-regulation of TF mRNA by ATRA was partially de novo protein synthesis-dependent and at least partially attributed to a mechanism of destabilizing TF mRNA. On the other hand, in addition to its modulation on mRNA, As2O3 could also induce an accelerated TF protein turnover. These distinct effects were corroborated with the properties of these agents in causing the degradation of PML-RARα protein. All three therapeutic agents, however, enhanced the potential of NB4 cells to stimulate the expression of TF and PCA in endothelium. Taken together, our data suggest that the rapid and distinct regulation of TF on APL cells by these therapeutic agents might at least partially contribute to their effects on APL coagulopathy.Keywords
This publication has 18 references indexed in Scilit:
- APMLRARα transgene initiates murine acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 1997
- Deciphering the pathogenesis of coagulation dysfunction in leukemiaLeukemia Research, 1996
- The Structural Biology of Expression and Function of Tissue FactorThrombosis and Haemostasis, 1991
- Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factorBiochemistry, 1990
- Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibodyThrombosis Research, 1990
- Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proceedings of the National Academy of Sciences, 1989
- Regional assignment of human tissue factor gene (F3) to chromosome 1p21-p22Somatic Cell and Molecular Genetics, 1988
- Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascadeCell, 1987
- In vitro generation of procoagulant activity by leukemic promyelocytes in reponse to cytotoxic drugsAmerican Journal of Hematology, 1985
- Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.Proceedings of the National Academy of Sciences, 1977